Low cost rotavirus vaccine in developing countries, ROTASIIL, a heat stable rotavirus vaccine, was approved by the Drug General Controller of India in 2017. The Government of India subsequently ordered 3.8 million doses of ROTASIIL for its Universal Immunization Program. 

ROTASIIL is based on a human-bovine reassortant rotavirus vaccine invented by the late Dr. Albert Kapikian and his colleagues at the National Institute of Allergy and Infectious Diseases (NIAID) and has been developed and manufactured by Serum Institute of India. In August 2018, NIAID/NIH and Serum Institute of India were recognized for this low-cost, temperature tolerant rotavirus vaccine for developing countries,  by the U.S. Patent and Trademark Office with a “Patents for Humanity” award.